|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
DRUG INTERACTIONS |
From Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (Dr Farid, Mr Ernest, Ms Li, Dr Winters, Dr Small); Lilly Research Center, Ltd, Eli Lilly and Company, Windlesham, UK (Mr Payne); and Daiichi Sankyo Pharma Development, Daiichi Sankyo, Inc, Edison, New Jersey (Dr Salazar). A portion of this work was presented at the 14th North American ISSX Meeting, Rio Grande, Puerto Rico, 2006, and was published in an abstract form in Drug Metab Rev. 2006;38(suppl 2):121.
Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)–dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate–induced platelet aggregation. This open-label, multiple-dose, 2-period, fixed-sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP2B6. Thirty healthy subjects received a single 150-mg oral dose of sustained-release bupropion. After a 7-day washout, a 60-mg prasugrel loading dose, followed by a 10-mg daily maintenance dose for 10 days, was administered. Bupropion (150 mg) was given with prasugrel on day 7 of this phase. Prasugrel weakly inhibited CYP2B6 activity as it increased bupropion Cmax and AUC0-
by 14% and 18%, respectively, and decreased hydroxybupropion Cmax and AUC0-
by 32% and 23%. These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6.
Key Words: Bupropion CYP2B6 inhibition hydroxybupropion prasugrel thienopyridines drug interactions
Address for reprints: Nagy A. Farid, PhD, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; e-mail: nafarid{at}lilly.com.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
C. S. Ernest II, M. A. Heathman, and R. E. Wrishko Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis J. Clin. Pharmacol., August 1, 2009; 49(8): 973 - 983. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Wrishko, C. S. Ernest II, D. S. Small, Y. G. Li, G. J. Weerakkody, J. R. Riesmeyer, W. L. Macias, S. Rohatagi, D. E. Salazar, E. M. Antman, et al. Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38 J. Clin. Pharmacol., August 1, 2009; 49(8): 984 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Veverka and J. M. Hammer Prasugrel: A New Thienopyridine Inhibitor Journal of Pharmacy Practice, April 1, 2009; 22(2): 158 - 165. [Abstract] [PDF] |
||||
![]() |
Y. Nishiya, K. Hagihara, T. Ito, M. Tajima, S.-i. Miura, A. Kurihara, N. A. Farid, and T. Ikeda Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel Drug Metab. Dispos., March 1, 2009; 37(3): 589 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Scott, R. M Norwood, and D. Parra P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel Ann. Pharmacother., January 1, 2009; 43(1): 64 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Williams, K. O. Jones, G. D. Ponsler, S. M. Lowery, E. J. Perkins, S. A. Wrighton, K. J. Ruterbories, M. Kazui, and N. A. Farid The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 Drug Metab. Dispos., July 1, 2008; 36(7): 1227 - 1232. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |